Residual neurocognitive features of long-term ecstasy users with minimal exposure to other drugs

Addiction

Volumn 106, Issue 4, 2011, Pages 777-786

  Halpern, John H ^a   Sherwood, Andrea R ^d,e,f   Hudson, James I ^b   Gruber, Staci ^c   Kozin, David ^a   Pope Jr, Harrison G ^b  

^a Laboratory for Integrative Psychiatry   (United States)

^b Biological Psychiatry Laboratory   (United States)

^c Cognitive and Clinical Neuroimaging Core Brain Imaging Center ^*  (United States)

^d MCLEAN HOSPITAL   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

Cognitive function; Ecstasy; MDMA; Neurotoxicity; Substance abuse

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; PSYCHEDELIC AGENT; SEROTONIN RECEPTOR AFFECTING AGENT;

ADDICTION; ADOLESCENT; ADULT; ARTICLE; CASE CONTROL STUDY; CHRONIC DISEASE; COGNITION; COGNITIVE DEFECT; DANCING; DOSE RESPONSE; DRUG EFFECT; EPIDEMIOLOGY; FEMALE; HUMAN; IMPULSIVENESS; MALE; MEMORY; METHODOLOGY; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PATHOPHYSIOLOGY; PHYSIOLOGY; PILOT STUDY; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; SLEEP DEPRIVATION; STATISTICAL MODEL; STATISTICS; SUBSTANCE ABUSE; VERBAL BEHAVIOR;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; CHRONIC DISEASE; COGNITION; COGNITION DISORDERS; CONFOUNDING FACTORS (EPIDEMIOLOGY); DANCING; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALLUCINOGENS; HUMANS; IMPULSIVE BEHAVIOR; LINEAR MODELS; MALE; MEMORY; MIDDLE AGED; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NEUROPSYCHOLOGICAL TESTS; PILOT PROJECTS; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN AGENTS; SLEEP DEPRIVATION; SUBSTANCE ABUSE DETECTION; SUBSTANCE-RELATED DISORDERS; VERBAL BEHAVIOR; YOUNG ADULT;

EID: 79952287560     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2010.03252.x     Document Type: Article

References (63)

1. Tanner-Smith E. E. Pharmacological content of tablets sold as 'ecstasy': results from an online testing service. Drug Alcohol Depend 2006; 83: 247-54.
2. United States Substance Abuse and Mental Health Services Administration. Results from the 2008 National Survey on Drug Use and Health: National Findings. NSDUH Series H-36, HHS Publication no. SMA 09-4434. Rockville, MD: Office of Applied Studies; 2009.
3. Lyvers M. Recreational ecstasy use and the neurotoxic potential of MDMA: current status of the controversy and methodological issues. Drug Alcohol Rev 2006; 25: 269-76.
4. Fang Y. X., Wang Y. B., Shi J., Liu Z. M., Lu L. Recent trends in drug abuse in China. Acta Pharmacol Sin 2006; 27: 140-4.
5. Schifano F., Corkery J., Naidoo V., Oyefeso A., Ghodse H. Overview of amphetamine-type stimulant mortality data-UK, 1997-2007. Neuropsychobiology 2010; 61: 122-30.
6. Capela J. P., Carmo H., Remiao F., Bastos M. L., Meisel A., Carvalho F. Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview. Mol Neurobiol 2009; 39: 210-71.
7. Gudelsky G. A., Yamamoto B. K. Actions of 3, 4-methylenedioxymethamphetamine (MDMA) on cerebral dopaminergic, serotonergic and cholinergic neurons. Pharmacol Biochem Behav 2008; 90: 198-207.
8. Cadet J. L., Krasnova I. N., Jayanthi S., Lyles J. Neurotoxicity of substituted amphetamines: molecular and cellular mechanisms. Neurotox Res 2007; 11: 183-202.
9. Baumann M. H., Wang X., Rothman R. B. 3, 4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings. Psychopharmacology (Berl) 2007; 189: 407-24.
10. Cole J. C., Sumnall H. R. Altered states: the clinical effects of Ecstasy. Pharmacol Ther 2003; 98: 35-58.
11. Gouzoulis-Mayfrank E., Daumann J. Neurotoxicity of methylenedioxyamphetamines (MDMA; ecstasy) in humans: how strong is the evidence for persistent brain damage? Addiction 2006; 101: 348-61.
12. Kalechstein A. D., De La Garza R. II, Mahoney J. J. III, Fantegrossi W. E., Newton T. F. MDMA use and neurocognition: a meta-analytic review. Psychopharmacology (Berl) 2007; 189: 531-7.
13. Rogers G., Elston J., Garside R., Roome C., Taylor R., Younger P. etal. The harmful health effects of recreational ecstasy: a systematic review of observational evidence. Health Technol Assess 2009; 13: iii-iv, ix-xii, 1-315.
14. Mithoefer M. C., Wagner M. T., Mithoefer A. T., Jerome I., Doblin R. The safety and efficacy of {+/-}3, 4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J Psychopharmacol 2010; Epub ahead of print 19 June 2010.
15. Halpern J. H., Pope H. G., Jr., Sherwood A. R., Barry S., Hudson J. I., Yurgelun-Todd D. Residual neuropsychological effects of illicit 3, 4-methylenedioxymethamphetamine (MDMA) in individuals with minimal exposure to other drugs. Drug Alcohol Depend 2004; 75: 135-47.
16. Bedi G., Redman J. Ecstasy use and higher-level cognitive functions: weak effects of ecstasy after control for potential confounds. Psychol Med 2008; 38: 1319-30.
17. Gouzoulis-Mayfrank E., Daumann J. The confounding problem of polydrug use in recreational ecstasy/MDMA users: a brief overview. J Psychopharmacol 2006; 20: 188-93.
18. Cho K. Chronic 'jet lag' produces temporal lobe atrophy and spatial cognitive deficits. Nat Neurosci 2001; 4: 567-8.
19. First M., Spitzer R., Gibbon M., Williams J. Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition. New York: Biometrics Research Department, New York State Psychiatric Institute; 2001.
20. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62.
21. Hamilton M. A rating scale for anxiety. Br J Med Psychol 1959; 32: 50-5.
22. Derogatis L. Symptom Checklist-90-R. Administration, Scoring, and Procedures Manual. Minneapolis, MN: National Computer Systems, Inc.; 1994.
23. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn (DSM-IV). Washington, DC: American Psychiatric Association; 1994.
24. Ward M. F., Wender P. H., Reimherr F. W. The Wender Utah Rating Scale: an aid in the retrospective diagnosis of childhood attention deficit hyperactivity disorder. Am J Psychiatry 1993; 150: 885-90.
25. DuPaul G. J. Parent and teacher ratings of ADHD symptoms: psychometric properties in a community-based sample. J Clin Child Psychol 1991; 20: 245-53.
26. Pope H. G., Jr., Gruber A. J., Hudson J. I., Huestis M. A., Yurgelun-Todd D. Neuropsychological performance in long-term cannabis users. Arch Gen Psychiatry 2001; 58: 909-15.
27. Wechsler D. Wechsler Adult Intelligence Scale-Revised Manual. Cleveland, OH: Psychological Corporation; 1981.
28. Osterrieth R. Le test de copie d'une figure complexe [The test of copying a complex figure]. Arch Psychol 1944; 30: 206-356.
29. Heaton R. Wisconsin Card Sorting Test Manual. Odessa, FL: Psychological Assessment Resources; 1981.
30. Reitan R., Wolfson D. The Halstead-Reitan Neuropsychological Test Battery: Theory and Clinical Interpretation, 2nd edn. Tucson, AZ: Neuropsychology Press; 1993.
31. Burke H. Raven's progressive matrices: more on norms, reliability, and validity. J Clin Psychol 1985; 41: 231-5.
32. Lezak M. Neuropsychological Assessment, 3rd edn. New York: Oxford University Press; 1995.
33. Stroop J. Studies of interference in serial verbal reactions. J Exp Psychol 1935; 18: 643-62.
34. Delis D. C., Kramer J. H., Kaplan E., Ober B. A. California Verbal Learning Test Manual, Version 1. San Antonio, TX: The Psychological Corporation; 1987.
35. Wechsler D. Wechsler Memory Scale, 3rd edn. San Antonio, TX: The Psychological Corporation; 1997.
36. Levine B., Dawson D., Boutet I., Schwartz M. L., Stuss D. T. Assessment of strategic self-regulation in traumatic brain injury: its relationship to injury severity and psychosocial outcome. Neuropsychology 2000; 14: 491-500.
37. Bechara A., Damasio A. R., Damasio H., Anderson S. W. Insensitivity to future consequences following damage to human prefrontal cortex. Cognition 1994; 50: 7-15.
38. Tiffin J., Asher E. J. The purdue pegboard: norms and studies of reliability and validity. J Appl Psychol 1948; 32: 234-47.
39. Beck A. T., Ward C. H., Mendelson M., Mock J., Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561-71.
40. Berger R. L., Hsu J. C. Bioequivalence trials, intersection-union tests and equivalence confidence sets. Stat Sci 1996; 11: 283-302.
41. Schuirmann D. J. A comparison of the 2 one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987; 15: 657-80.
42. Rothman K., Greenland S. Modern Epidemiology, 2nd edn. Philadelphia, PA: Lipppincott-Raven; 1998.
43. Feise R. J. Do multiple outcome measures require p-value adjustment? BMC Med Res Methodol 2002; 2: 8.
44. Savitz D. A., Olshan A. F. Multiple comparisons and related issues in the interpretation of epidemiologic data. Am J Epidemiol 1995; 142: 904-8.
45. Pope H. G., Jr. Cannabis, cognition, and residual confounding. JAMA 2002; 287: 1172-4.
46. Pope H. G., Jr., Gruber A. J., Hudson J. I., Cohane G., Huestis M. A., Yurgelun-Todd D. Early-onset cannabis use and cognitive deficits: what is the nature of the association? Drug Alcohol Depend 2003; 69: 303-10.
47. Roiser J. P., Rogers R. D., Sahakian B. J. Neuropsychological function in ecstasy users: a study controlling for polydrug use. Psychopharmacology (Berl) 2007; 189: 505-16.
48. Pirona A., Morgan M. An investigation of the subacute effects of ecstasy on neuropsychological performance, sleep and mood in regular ecstasy users. J Psychopharmacol 2009.
49. Clark L., Robbins T. W., Ersche K. D., Sahakian B. J. Reflection impulsivity in current and former substance users. Biol Psychiatry 2006; 60: 515-22.
50. Verdejo-Garcia A., Lawrence A. J., Clark L. Impulsivity as a vulnerability marker for substance-use disorders: review of findings from high-risk research, problem gamblers and genetic association studies. Neurosci Biobehav Rev 2008; 32: 777-810.
51. Clark L., Roiser J. P., Robbins T. W., Sahakian B. J. Disrupted 'reflection' impulsivity in cannabis users but not current or former ecstasy users. J Psychopharmacol 2009; 23: 14-22.
52. de Win M. M., Reneman L., Jager G., Vlieger E. J., Olabarriaga S. D., Lavini C. etal. A prospective cohort study on sustained effects of low-dose ecstasy use on the brain in new ecstasy users. Neuropsychopharmacology 2007; 32: 458-70.
53. Nigg J. T., Wong M. M., Martel M. M., Jester J. M., Puttler L. I., Glass J. M. etal. Poor response inhibition as a predictor of problem drinking and illicit drug use in adolescents at risk for alcoholism and other substance use disorders. J Am Acad Child Adolesc Psychiatry 2006; 45: 468-75.
54. Wong M. M., Nigg J. T., Zucker R. A., Puttler L. I., Fitzgerald H. E., Jester J. M. etal. Behavioral control and resiliency in the onset of alcohol and illicit drug use: a prospective study from preschool to adolescence. Child Dev 2006; 77: 1016-33.
55. Schilt T., Koeter M. W., Smal J. P., Gouwetor M. N., van den Brink W., Schmand B. Long-term neuropsychological effects of ecstasy in middle-aged ecstasy/polydrug users. Psychopharmacology (Berl) 2009.
56. Schilt T., de Win M. M., Jager G., Koeter M. W., Ramsey N. F., Schmand B. etal. Specific effects of ecstasy and other illicit drugs on cognition in poly-substance users. Psychol Med 2008; 38: 1309-17.
57. Quednow B. B., Jessen F., Kuhn K. U., Maier W., Daum I., Wagner M. Memory deficits in abstinent MDMA (ecstasy) users: neuropsychological evidence of frontal dysfunction. J Psychopharmacol 2006; 20: 373-84.
58. Indlekofer F., Piechatzek M., Daamen M., Glasmacher C., Lieb R., Pfister H. etal. Reduced memory and attention performance in a population-based sample of young adults with a moderate lifetime use of cannabis, ecstasy and alcohol. J Psychopharmacol 2009; 23: 495-509.
59. McCann U. D., Wilson M. J., Sgambati F. P., Ricaurte G. A. Sleep deprivation differentially impairs cognitive performance in abstinent methylenedioxymethamphetamine ('ecstasy') users. J Neurosci 2009; 29: 14050-6.
60. Montgomery C., Fisk J. E., Wareing M., Murphy P. Self reported sleep quality and cognitive performance in ecstasy users. Hum Psychopharmacol 2007; 22: 537-48.
61. Schilt T., de Win M. M., Koeter M., Jager G., Korf D. J., van den Brink W. etal. Cognition in novice ecstasy users with minimal exposure to other drugs: a prospective cohort study. Arch Gen Psychiatry 2007; 64: 728-36.
62. Gouzoulis-Mayfrank E., Fischermann T., Rezk M., Thimm B., Hensen G., Daumann J. Memory performance in polyvalent MDMA (ecstasy) users who continue or discontinue MDMA use. Drug Alcohol Depend 2005; 78: 317-23.
63. Laws K. R., Kokkalis J. Ecstasy (MDMA) and memory function: a meta-analytic update. Hum Psychopharmacol 2007; 22: 381-8.